Get started

Financials · CSTL

Castle Biosciences Inc. (CSTL) financials

For the twelve months ended Sep 30, 2026, Castle Biosciences Inc. reported $377.13M of revenue and -$23.01M of net income.

Revenue, TTM
$377.13M
Revenue growth, YoY
+9.8%
Net income, TTM
-$23.01M
Net margin
-6.1%
Free cash flow, TTM
$3.96M
EPS, diluted, TTM
-$0.75
Cash
$77.99M
Total debt
$10.08M
P/S
2.81
Market cap
$1.06B
Annual revenue$344.23M
FY2018FY2025
Annual net income-$24.16M
FY2018FY2025
Annual free cash flow$28.33M
FY2018FY2025

CSTL revenue and earnings growth

CSTL revenueQ3 2026$102.89M

Quarter YoY
+23.9%
QoQ
-0.6%
FY YoY
+3.7%
5Y CAGR
+40.6%

CSTL revenue was $102.89M in fiscal Q3 2026 (ended Sep 30, 2026), up 23.9% from a year earlier and down 0.6% from the prior quarter. For the full fiscal 2025 it was $344.23M, up 3.7% from fiscal 2024. Compound annual growth was +40.6% over 5 years. It rose in each of the last 7 fiscal years. Fiscal 2025 is the highest of the 8 fiscal years on file.

CSTL net incomeQ3 2026-$4.10M

CSTL net income was -$4.10M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$501.0K a year earlier. For the full fiscal 2025 it was -$24.16M, compared with $18.25M in fiscal 2024.

CSTL EPSQ3 2026-$0.13

CSTL diluted EPS was -$0.13 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.02 a year earlier. For the full fiscal 2025 it was -$0.83, compared with $0.62 in fiscal 2024.

CSTL free cash flowQ3 2026$12.25M

Quarter YoY
+57.1%
QoQ
+87.0%
FY YoY
-22.5%
5Y CAGR
+40.8%

CSTL free cash flow was $12.25M in fiscal Q3 2026 (ended Sep 30, 2026), up 57.1% from a year earlier and up 87.0% from the prior quarter. For the full fiscal 2025 it was $28.33M, down 22.5% from fiscal 2024. Compound annual growth was +40.8% over 5 years.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$344.23M$332.07M$219.79M$137.04M$94.08M$62.65M$51.87M$22.79M
Cost of revenue$71.03M$60.20M$44.98M$32.01M$15.82M$9.69M$7.31M$5.30M
Gross profit$273.20M$271.86M$174.81M$105.03M$78.26M$52.96M$44.55M$17.49M
Research and development$51.85M$52.04M$53.62M$44.90M$29.65M$13.26M$7.38M$4.85M
Selling, general and admin$229.32M$200.05M$180.15M$143.00M$86.74M$48.13M$29.84M$16.47M
Operating income-$42.81M$8.67M-$67.98M-$72.86M-$40.08M-$6.54M$7.33M-$3.84M
Interest expense$86.0K$577.0K$11.0K$17.0K$1.0K$2.63M$4.57M$2.27M
Income tax-$5.36M$3.32M$101.0K-$1.77M-$8.72M$84.0K$72.0K$9.0K
Net income-$24.16M$18.25M-$57.47M-$67.14M-$31.29M-$10.28M$5.28M-$6.37M
EPS, basic-$0.83$0.66-$2.14-$2.58-$1.24-$0.54$0.35-$5.33
EPS, diluted-$0.83$0.62-$2.14-$2.58-$1.24-$0.54-$0.21-$5.33
Diluted shares29.0M29.3M26.8M26.1M25.1M18.9M8.7M1.9M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$116.73M$119.71M$98.84M$122.95M$329.63M$409.85M$98.84M$4.48M
Short-term investments$182.78M$173.42M$144.26M-----
Receivables$43.38M$51.22M$38.30M$23.48M$17.28M$12.76M$14.65M$12.09M
Inventory$10.25M$8.13M$7.94M$3.98M$2.02M$2.22M$1.24M$882.0K
Current assets$361.10M$360.15M$295.63M$292.29M$353.74M$429.59M$116.68M$18.13M
Goodwill$10.70M$10.70M$10.70M$10.70M$0---
Total assets$578.56M$531.24M$453.34M$447.33M$462.57M$439.33M$119.75M$22.41M
Current liabilities$68.68M$49.39M$47.67M$36.13M$24.89M$20.88M$15.29M$6.74M
Short-term debt$417.0K$278.0K$0--$0$5.83M$0
Long-term debt$9.64M$9.74M$0--$0$19.29M$24.50M
Total debt$10.06M$10.02M$0--$0$25.12M$24.50M
Total liabilities$107.68M$75.40M$62.07M$48.18M$50.83M$23.64M$34.63M$32.48M
Shareholders' equity$470.87M$455.83M$391.27M$399.15M$411.74M$415.69M$85.11M-$56.57M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow$64.35M$64.87M-$5.63M-$41.66M-$18.98M$9.87M$7.01M-$12.29M
Capital expenditures$36.02M$28.33M$13.62M$5.63M$3.48M$4.75M$937.0K$277.0K
Free cash flow$28.33M$36.54M-$19.25M-$47.29M-$22.47M$5.11M$6.08M-$12.57M
Investing cash flow-$60.37M-$50.14M-$16.18M-$166.54M-$66.66M-$4.75M-$937.0K-$277.0K
Financing cash flow-$6.96M$6.14M-$2.30M$1.51M$5.42M$305.89M$88.29M$15.84M
Stock-based compensation$45.89M$50.32M$51.22M$36.32M$21.74M$8.31M$1.25M$294.0K
Depreciation and amortization$40.77M$16.00M$12.33M$10.54M$3.41M$472.0K--

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY3.7%51.1%60.4%45.7%50.2%20.8%127.6%-
Gross margin79.4%81.9%79.5%76.6%83.2%84.5%85.9%76.8%
Operating margin-12.4%2.6%-30.9%-53.2%-42.6%-10.4%14.1%-16.8%
Net margin-7.0%5.5%-26.1%-49.0%-33.3%-16.4%10.2%-27.9%
Free cash flow margin8.2%11.0%-8.8%-34.5%-23.9%8.2%11.7%-55.2%
Return on equity-5.1%4.0%-14.7%-16.8%-7.6%-2.5%6.2%-
Return on assets-4.2%3.4%-12.7%-15.0%-6.8%-2.3%4.4%-28.4%
Current ratio5.267.296.208.0914.2120.587.632.69
Debt to equity0.020.020.00--0.000.30-

Source: XBRL data Castle Biosciences Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

CSTL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
CSTL$377.13M+9.8%-$23.01M-6.1%$1.06B
UNH$449.66B+3.3%$15.88B3.5%$363.00B
ELV$201.83B+3.6%$5.13B2.5%$92.83B
CI$286.32B+6.8%$5.99B2.1%$79.88B
HUM$154.19B+22.0%$1.25B0.8%$52.61B
NTRA$2.91B+37.4%-$164.71M-5.7%$45.24B
CNC$203.90B+9.7%$1.46B0.7%$34.75B
ILMN$4.54B+5.8%$895.00M19.7%$32.49B
LH$14.59B+6.0%$1.00B6.9%$30.12B

CSTL FAQ

9 questions
  • What is CSTL revenue?
    Castle Biosciences Inc. (CSTL) reported $377.13M of revenue for the twelve months ended Sep 30, 2026. That is up 9.8% from the year before. Revenue for fiscal 2025 was $344.23M.
  • Is CSTL profitable?
    No. Castle Biosciences Inc. reported a net loss of $23.01M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does CSTL have?
    Castle Biosciences Inc. reported $77.99M in cash and cash equivalents and $10.08M of debt on its most recent balance sheet in SEC filings.
  • How fast is CSTL revenue growing?
    Castle Biosciences Inc.'s revenue changed +3.7% in fiscal 2025, to $344.23M. Its compound annual growth rate was +40.6% over 5 years.
  • What is CSTL gross margin?
    Castle Biosciences Inc.'s gross profit was $290.66M on $377.13M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 77.1%.
  • What is CSTL free cash flow?
    Castle Biosciences Inc. generated $3.96M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $39.74M less capital expenditures.
  • What is CSTL earnings per share?
    Diluted earnings per share were -$0.75 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did CSTL last report financial results?
    The latest statements here come from Castle Biosciences Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.
  • Where does this CSTL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Castle Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.